ABBV Chairman of the Board and CEO GONZALEZ RICHARD A also sold 39,000 shares, at a stock price of $63.8. For the prior quarter revenue for the stock hit $5.96B, with EPS at $1.15.
Advertisement
In a related news, Schumacher Laura J, Officer (Executive Vice President) of AbbVie Inc., unloaded 186,106 shares at an average price of $60.07 on June 24, 2016. The Average price target is noted at $71.46, this average price is calculated and based on coming up with go through the consensus of analysts and stock’s current price is placed at $64.12. The insider owns 194,138 shares as of Jun 24, 2016, now worth $12448129. For the current year the company’s revenue estimates are $25.81B compared to low analyst estimates of $25.39B and high estimates of $26.16B according to the projection of 17 analysts. Over the one year trading period, the stock has a high price of $68.12 and its low price is recorded at $45.45. For the reporting quarter, equity analysts expect the stock to deliver $1.2 in earnings per share (EPS). Morgan Stanley analysts downgraded the stock to Equal-Weight from Overweight. They issued an outperform rating and a $82.00 target price for the company.
Raymond James issued their verdict on AbbVie Inc (NYSE:ABBV) recently. The company has a consensus rating of Buy and a consensus price target of $69.10.
AbbVie Inc NYSE:ABBV has a 50 day moving average of 65.19 United States dollars and a 200 Day Moving Average share price is recorded at 60.45 USD. The company reported $1.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.20 by $0.06. The company market cap of 9.12B.
Advertisement
AbbVie Inc (NYSE:ABBV) performance over the past one year advanced 8.15%, during the last six months the stock rose 15.79%. Revenue for the same quarter is predicted to arrive at $6.53B. That is compared with the $1.13 in earnings per share it reported during the same period previous year. The Company develops and markets therapies that address a range of diseases. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, and endocrinology products and other products. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions.
